Public Biobanks: Calculation and Recovery of Costs

Clément, Bruno; Yuille, Martin; Zaltoukal, Kurt; Wichmann, Heinz‐Erich; Anton, Gabriele; Parodi, Brunella; Kozera, Łukasz; Bréchot, Christian; Hofman, Paul; Dagher, Georges

doi:10.1126/scitranslmed.3010444

Cited by 51 publications

(45 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 Furthermore, in a study published in 2014, Clément et al assessed the real costs of operational processes in 20 European and US biobanks handling either human samples or microorganisms implicated in human health and disease. 20 The estimated real costs substantially exceeded the fees charged by the biobank. For example, real costs for a tumor approximated €1,500 ($1,680), while those for DNA extracted from blood were estimated at €460 ($515).…”

Section: Discussionmentioning

confidence: 99%

Biobank sustainability: current status and future prospects

Doucet¹,

Yuille²,

Georghiou³

et al. 2017

BSAM

Self Cite

View full text Add to dashboard Cite

Abstract:Biobanks play an important role in biomedical research that aims to understand cellular and molecular mechanisms underlying the development of diseases, and to improve interventions for human health. Despite financial support from mixed public funding streams, long-term sustainability of public biobanks remains a major concern. Review of the literature demonstrates that total cost-recovery strategies, as well as commercialization of research results or derived products, may not represent the best way to reach and maintain sustainability. Public biobanks require support by long-term investment and commitment from public and governmental sources, as well as support from industrial users. In this regard, this study suggests strategies to improve long-term sustainability, such as sample-sharing and biobank consolidation to reduce unit costs, embedding public biobanks in health care systems, and working to implement global funding mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Biobank sustainability: current status and future prospects

Doucet¹,

Yuille²,

Georghiou³

et al. 2017

BSAM

Self Cite

View full text Add to dashboard Cite

show abstract

“…[17][18][19][20][21] Analyses have found that, at most, 5%-25% of operation costs could be recovered through distribution fees because the actual cost of collecting and distributing tissue is prohibitive for the requesting researcher. 22,23 Even with aggressive marketing, the demand for biospecimens varies and is irregular based on individual researcher needs, research funding, and availability of required samples. 24 Furthermore, even in ideal circumstances, only a percentage of collected samples will be distributed, which would necessitate adding non-distributed specimen collection and storage costs into the cost recovery fees, making biospecimens even more expensive.…”

Section: The Biobank Core Facilitymentioning

confidence: 99%

Sustainability in a Hospital-Based Biobank and University-Based DNA Biorepository: Strategic Roadmaps

Seiler

Eschbacher

Bowser

et al. 2015

Biopreservation and Biobanking

View full text Add to dashboard Cite

Sustainability in the biobanking community has recently become an important and oft-discussed issue as biorepositories struggle to balance limited external funding and complex cost recovery models with high operating costs and the desire to provide the highest quality materials and services to the research community. A multi-faceted view of biobanking sustainability requires consideration of operational and social sustainability in addition to the historical focus exclusively on financial sustainability. Planning and implementing this three pillar model creates a well-rounded biorepository that meets the needs of all the major stakeholders: the funders, the patients/depositors, and the researcher recipients. Often the creation of a detailed business plan is the first step to develop goals and objectives that lead down a path towards sustainability. The definition of sustainability and the complexity of a sustainable business plan may differ for each biorepository. The DNASU Plasmid Repository at Arizona State University stores and distributes DNA plasmids to researchers worldwide, and the Biobank Core Facility at St. Joseph's Hospital and Barrow Neurological Institute consents patients and collects, stores, and distributes human tissue and blood samples. We will discuss these two biorepositories, their similar and different approaches to sustainability and business planning, their challenges in creating and implementing their sustainability plan, and their responses to some of these challenges. From these experiences, the biobanks share lessons learned about planning for sustainability that are applicable to all biorepositories.

show abstract

“…Additionally, this allows inclusion of clinical samples that have been processed for biobanking, or to use such samples for replication or validation. Biobanks collect large numbers of samples such as tissues or DNA (deoxyribonucleic acid) and the associated patient information, which is highly valuable for retrospective biomarker studies [6–9]. Exploratory screens for candidate biomarkers mainly rely on the use of patient specimens, which are obtained in small quantities, while also biobanks often contain limited quantities of patient material.…”

Section: Introductionmentioning

confidence: 99%

Genome-wide epigenomic profiling for biomarker discovery

2016

View full text Add to dashboard Cite

A myriad of diseases is caused or characterized by alteration of epigenetic patterns, including changes in DNA methylation, post-translational histone modifications, or chromatin structure. These changes of the epigenome represent a highly interesting layer of information for disease stratification and for personalized medicine. Traditionally, epigenomic profiling required large amounts of cells, which are rarely available with clinical samples. Also, the cellular heterogeneity complicates analysis when profiling clinical samples for unbiased genome-wide biomarker discovery. Recent years saw great progress in miniaturization of genome-wide epigenomic profiling, enabling large-scale epigenetic biomarker screens for disease diagnosis, prognosis, and stratification on patient-derived samples. All main genome-wide profiling technologies have now been scaled down and/or are compatible with single-cell readout, including: (i) Bisulfite sequencing to determine DNA methylation at base-pair resolution, (ii) ChIP-Seq to identify protein binding sites on the genome, (iii) DNaseI-Seq/ATAC-Seq to profile open chromatin, and (iv) 4C-Seq and HiC-Seq to determine the spatial organization of chromosomes. In this review we provide an overview of current genome-wide epigenomic profiling technologies and main technological advances that allowed miniaturization of these assays down to single-cell level. For each of these technologies we evaluate their application for future biomarker discovery. We will focus on (i) compatibility of these technologies with methods used for clinical sample preservation, including methods used by biobanks that store large numbers of patient samples, and (ii) automation of these technologies for robust sample preparation and increased throughput.

show abstract

Public Biobanks: Calculation and Recovery of Costs

Cited by 51 publications

References 7 publications

Biobank sustainability: current status and future prospects

Biobank sustainability: current status and future prospects

Sustainability in a Hospital-Based Biobank and University-Based DNA Biorepository: Strategic Roadmaps

Genome-wide epigenomic profiling for biomarker discovery

Contact Info

Product

Resources

About